环氧合酶/5-脂氧合酶双效抑制剂研究进展  

Dual cyclooxygenase /5-lipoxygen inhibitor: research advances

作　　者：任小姗[1] 陈志涛[1] 陈刚[1] 

机构地区：[1]重庆大学化学化工学院,重庆400044

出　　处：《国际药学研究杂志》2013年第5期550-556,共7页Journal of International Pharmaceutical Research

基　　金：重庆市自然科学基金资助项目(2011BB5090);中央高校基本科研业务费CDJRC10220010

摘　　要：新型非甾体类抗炎药环氧合酶/5-脂氧合酶(COX/5-LOX)双效抑制剂可同时抑制花生四烯酸经COX和5-LOX途径代谢,减少前列腺素和白三烯的生物合成,有效降低了传统非甾体类抗炎药的不良反应。最新酶水平实验、细胞实验及动物实验研究证实双效抑制剂在肿瘤的治疗中起重要作用,相关作用机制研究已经成为热点,同时双效抑制剂在动脉粥样硬化及其他疾病治疗方面也显现出一定疗效。本文主要对COX/5-LOX双效抑制剂用于上述多种疾病的治疗研究进行介绍,并对近期出现的COX/5-LOX双效抑制剂类化合物进行总结归纳。Dual cyclooxygenase/5-lipoxygense（COX/5-LOX） inhibitor can decrease the side effect of traditional non-steroidal anti-inflammatory drugs through inhibiting the biosynthesis of prostaglandin and leukotriene simultaneously. It has been confirmed that COX/5-LOX inhibitors are highly effective in curing tumour by experiments. And the dual COX/5-LOX inhibitors play an important role in the treatment of atherosclerosis and many other diseases. In this paper, the novel chemical entities of dual COX/5-LOX inhibitors and their new pharmaceutical potencies are reviewed.

关 键 词：环氧合酶 脂氧合酶 炎症 肿瘤 动脉粥样硬化 

分 类 号：TQ464.8[化学工程—制药化工] R96[医药卫生—药理学]